Physician profile
Holly A Dickson
NPI 1235145715
$2,969.53
in general payments reported to CMS, 2019-2025
23 companies · $407 in 2025
The $407 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $475 · 2020: $334 · 2021: $426 · 2022: $298 · 2023: $538 · 2024: $490 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.50 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $557.34 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $428.33 | 2021-2025 | |
| Astellas Pharma US INC | $424.44 | 2019-2025 | Veozah |
| Hologic Sales and Service, LLC | $315.16 | 2019-2025 | Thinprep 2000 Processor, Omni Hysteroscope, Aptima |
| Therapeuticsmd, INC. | $258.73 | 2019-2022 | |
| Allergan, INC. | $233.24 | 2019-2022 | |
| Pfizer INC. | $92.48 | 2019-2023 | |
| Revance Therapeutics, INC. | $77.00 | 2025 | Daxxify |
| Bayer Healthcare Pharmaceuticals INC. | $72.24 | 2020-2022 | |
| Coopersurgical, INC. | $60.73 | 2019 | |
| Merck Sharp & Dohme LLC | $59.88 | 2019-2020 | |
| Boston Scientific Corporation | $54.78 | 2024 | Solyx Sis System |
| Novo Nordisk INC | $51.94 | 2023-2024 | Wegovy, Saxenda |
| Currax Pharmaceuticals LLC | $51.02 | 2021-2022 | |
| Minerva Surgical, INC | $35.78 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $32.31 | 2021 | |
| Avion Pharmaceuticals | $32.29 | 2021 | |
| Galderma Laboratories, L.P. | $28.90 | 2020-2021 | |
| Exeltis, USA INC. | $28.60 | 2021 | |
| Smith+Nephew, INC. | $24.16 | 2024 | Stravix |
| Biohaven Pharmaceutical Holding Company LTD. | $20.97 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.94 | 2019 | |
| Horizon Therapeutics Plc | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Dickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.